COVID-19住院患者急性肾损伤的结局
本研究为回顾性队列研究,纳入2020年3月1日至4月27日纽约大都会13家医院收治的9657例COVID-19住院患者,随访至出院。结果显示急性肾损伤(AKI)发生率为38.4/1000患者日,AKI与住院死亡风险显著相关,且需透析者风险更高;存活AKI患者中多数肾功能恢复,但部分需透析者出院时仍依赖透析。
要点
- COVID-19住院患者AKI发生率为38.4/1000患者日。
- AKI 1-3期和AKI 3D的调整死亡风险分别为无AKI者的3.4倍和6.4倍。
- 存活AKI 1-3期患者74.1%出院时肾功能恢复;存活AKI 3D患者30.6%出院时仍透析。
核心结论
- COVID-19住院患者发生AKI与显著增加的住院死亡风险相关,且需透析者风险更高。
研究设计与样本
- 回顾性队列研究,纳入2020年3月1日至4月27日纽约大都会13家医院收治的9657例COVID-19住院患者(年龄≥18岁),随访至出院。
主要发现
- AKI发生率为38.4/1000患者日。
- 无AKI、AKI未透析(1-3期)、AKI透析(3D)患者的住院死亡率分别为10.8、31.1、37.5/1000患者日。
- 以无AKI为参照,AKI 1-3期和AKI 3D的住院死亡风险HR分别为5.6(95%CI 5.0-6.3)和11.3(95%CI 9.6-13.1);调整人口学、合并症和疾病严重度后,调整HR分别为3.4(95%CI 3.0-3.9)和6.4(95%CI 5.5-7.6)。
- 存活AKI 1-3期患者中74.1%出院时肾功能恢复;存活AKI 3D患者中30.6%出院时仍透析。
- 出院时仍需透析的唯一独立危险因素为院前慢性肾脏病(调整OR 9.3,95%CI 2.3-37.8)。
临床怎么用
- 对COVID-19住院患者应监测AKI发生,AKI尤其需透析者死亡风险高,需加强管理。
- 存活AKI患者出院时需评估肾功能恢复情况,尤其需透析者应关注持续透析风险。
- 院前慢性肾脏病是AKI透析患者出院时仍需透析的独立危险因素,应重点随访。
局限性
- 回顾性观察性研究,仅限于COVID-19大流行高峰期的纽约大都会地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19) and acute kidney injury (AKI) are not well understood. The goal of this study was to investigate the survival and kidney outcomes of these patients. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Patients (aged≥18 years) hospitalized with COVID-19 at 13 hospitals in metropolitan New York between March 1, 2020, and April 27, 2020, followed up until hospital discharge. EXPOSURE: AKI. OUTCOMES: Primary outcome: in-hospital death. SECONDARY OUTCOMES: requiring dialysis at discharge, recovery of kidney function. ANALYTICAL APPROACH: Univariable and multivariable time-to-event analysis and logistic regression. RESULTS: Among 9,657 patients admitted with COVID-19, the AKI incidence rate was 38.4/1,000 patient-days. Incidence rates of in-hospital death among patients without AKI, with AKI not requiring dialysis (AKI stages 1-3), and with AKI receiving dialysis (AKI 3D) were 10.8, 31.1, and 37.5/1,000 patient-days, respectively. Taking those without AKI as the reference group, we observed greater risks for in-hospital death for patients with AKI 1-3 and AKI 3D (HRs of 5.6 [95% CI, 5.0-6.3] and 11.3 [95% CI, 9.6-13.1], respectively). After adjusting for demographics, comorbid conditions, and illness severity, the risk for death remained higher among those with AKI 1-3 (adjusted HR, 3.4 [95% CI, 3.0-3.9]) and AKI 3D (adjusted HR, 6.4 [95% CI, 5.5-7.6]) compared with those without AKI. Among patients with AKI 1-3 who survived, 74.1% achieved kidney recovery by the time of discharge. Among those with AKI 3D who survived, 30.6% remained on dialysis at discharge, and prehospitalization chronic kidney disease was the only independent risk factor associated with needing dialysis at discharge (adjusted OR, 9.3 [95% CI, 2.3-37.8]). LIMITATIONS: Observational retrospective study, limited to the NY metropolitan area during the peak of the COVID-19 pandemic. CONCLUSIONS: AKI in hospitalized patients with COVID-19 was associated with significant risk for death.
引用
- Ng JH, Hirsch JS, Hazzan A, et al. Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury. Am J Kidney Dis. 2020. PMID: 32961245. doi:10.1053/j.ajkd.2020.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。